Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 c » 25 c (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 c » 25 c (Expand Search)
-
11601
-
11602
-
11603
Data Sheet 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.xlsx
Published 2025“…</p>Methods<p>We investigated the effects of two FDA-approved metabolic agents—Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion—in male 5xFAD mice, a transgenic model of AD. …”
-
11604
Supplementary file 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.docx
Published 2025“…</p>Methods<p>We investigated the effects of two FDA-approved metabolic agents—Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion—in male 5xFAD mice, a transgenic model of AD. …”
-
11605
-
11606
-
11607
Supplementary Material for: Pregnane-Oximino-Alkyl-Amino-Ether Compound as a Novel Class of TGR5 Receptor Agonist Exhibiting Antidiabetic and Anti-Dyslipidemic Activities
Published 2021“…These beneficial effects of compound <b>14b</b> were associated with the activation of the G-protein-coupled bile acid receptor TGR5. <b><i>Conclusion:</i></b> Compound <b>14b</b> exhibits antidiabetic and anti-dyslipidemic activities through activating the TGR5 receptor system and can be developed as a lead for the management of type II diabetes and related metabolic complications.…”
-
11608
-
11609
-
11610
-
11611
-
11612
-
11613
-
11614
-
11615
-
11616
-
11617
-
11618
Percent binding of BKPyV VP1 serotype Ib1 to HEK293TT cells in the presence or absence of antibodies. Median fluorescent intensity of plots shown in Fig 3 were extracted using FlowJo 10.7.1 and normalized to 100% VP1 binding (VP1-Ib1 binding to HEK293TT cells in the absence of antibodies) and 0% VP1 binding (HEK293TT cells with detection antibody only). For mAb 319C07 and mAb P8D11 a concentration-dependent decrease in VP1 binding to the cells was observed. mAb 24C03 does not inhibit VP1 binding to HEK293TT cells. n = 1, 15000 cells analyzed per concentration.
Published 2025“…For mAb 319C07 and mAb P8D11 a concentration-dependent decrease in VP1 binding to the cells was observed. mAb 24C03 does not inhibit VP1 binding to HEK293TT cells. n = 1, 15000 cells analyzed per concentration.…”
-
11619
-
11620